ERBB2 and neoplasm: As it shown, the patients were at the age of (63.8 ± 12.5) years, 86.0% (37/43) were likely to have tumour grade of I-II, 97.7% (42/43) were ER/progesterone receptor (ER/PR)-positive and 88.4% (38/43) were HER2-negative.